Macro Group’s consolidated profit jumps 75.1% YoY in H1
Updated 8/1/2022 11:29:10 AM
Arab Finance: Macro Group Pharmaceutical (Macro Capital) (MCRO) reported a 75.05% year-on-year (YoY) hike in consolidated net profit attributable to the parent company for the first half (H1) of 2022, according to the consolidated financial statement filed to the Egyptian Exchange (EGX) on August 1st.
The group recorded a consolidated net profit attributable to the parent of EGP 71.35 million in H1 2022, compared to EGP 40.76 million in the same period of 2021.
Consolidated sales amounted to EGP 305.13 million in the six-month period ended June 30th, up from EGP 233.36 million in the year-ago period.
On the other hand, Macro Group achieved a standalone net profit after tax of EGP 72.33 million in H1 2022, versus a profit of EGP 41.36 million in H1 2021, according to the standalone financial statement.
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
